How excluding some benefits from value assessment of new drugs impacts innovation*
Sign Up to like & getrecommendations! Published in 2017 at "Health Economics"
DOI: 10.1002/hec.3507
Abstract: Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently exclude some drugs' option-related benefits, reducing their reimbursement chances, and making them less attractive R&D investments. We develop… read more here.
Keywords: assessment new; excluding benefits; drugs impacts; value assessment ... See more keywords